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Clinical review
Science, medicine, and the future
Microbicides in HIV prevention
Sheena McCormack, Richard Hayes, Charles J N Lacey, Anne M Johnson
In 1999 about 5.4 million people were newly infected
with HIV.1 In some countries public health pro›
grammes have achieved modest gains in reducing HIV
transmission through behavioural change, but the
worldwide picture is one of increasing rates of
infection. Although the use of condoms has slowly
increased in countries most severely affected by the
HIV epidemic, many vulnerable women are unable to
ensure they are used. An effective and affordable vagi›
nal microbicide, whose use could be controlled by
women, would represent an important addition to the
armamentarium against HIV infection. In this article
we examine current progress in microbicide develop›
ment and discuss their future role in HIV control.
Methods
We searched Medline using the key words and phrases
“microbicides,” “virucides,” and “vaginal microbicides.”
We also obtained the latest product information from
the Alliance for Microbicide Development (P Harri›
son, personal communication),2 and we asked
scientific colleagues involved in microbicide research
for their comments on products in preclinical
development.
Microbicides for controlling sexually
transmitted infections
Microbicides act by disrupting or disabling organisms
or block their entry into host cells by interfering with
cell surface receptors. Chemical agents have a long
history in the control of sexually transmitted
infections and fertility. Penile antiseptics were widely
promoted for controlling sexually transmitted disease
in both world wars, although their efficacy and
effectiveness remain uncertain.3 Intravaginal spermi›
cides have been marketed for decades but have had
limited popularity in the era of more reliable
contraceptive methods.
The development of microbicides has drawn on
existing contraceptive technology to develop safe,
effective, acceptable, and accessible agents. As with HIV
vaccines, progress with the development of effective
microbicides has been slow, and the results of early
trials of surfactants such as nonoxinol 9 were
disappointing. The Microbicides 2000 conference in
Washington, DC, provided new impetus to develop
such compounds, and several promising products are
now undergoing preclinical assessment.
Characteristics of an ideal microbicide
Laboratory evaluation of microbicidal activity must
take account of the physiological changes that occur
during sexual intercourse: compounds must retain
activity in the presence of semen and over a broad pH
range, ideally for several hours. Innovative methods to
assess this include the use of “in vivo” cervical tissue
from hysterectomy specimens.4 Activity against other
sexually transmitted infections is an advantage, but
products must not disrupt the normal vaginal flora,
and non›spermicidal microbicides should not be tera›
togenic. Agents and vehicles for delivery must be latex
compatible for use with condoms, and delivery systems
must ensure adequate distribution and retention in the
vagina. Methods to assess the latter are under develop›
ment and include the use of fluorescent probes and
magnetic resonance imaging. Topical microbicides
should show negligible systemic absorption and be
Predicted developments
New microbicides will enter efficacy (phase III)
trials in the next 5›10 years, and some may reach
completion (such as carrageenan, Buffer Gel,
dextrin sulphate, and PRO 2000)
One or more microbicides will have demonstrable
efficacy against HIV infection sufficient to justify
marketing the product
Research into low cost delivery systems will
intensify to improve acceptability for female and
male users
Careful consideration must be given to ethical
issues and to ensuring appropriate procedures for
informed consent
Microbicides will face the same challenges of
distribution and implementation as condoms,
which may ultimately remain more effective in
preventing HIV transmission
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free from local toxic effects. The use of surfactants has
been associated with disruption of genital epithelia,
which may enhance HIV transmission.5 6
Acceptability of products is likely to be key to their
widespread use. This will be enhanced by characteris›
tics such as low cost, long shelf life, tolerance to high
ambient temperature, and ease of use. Products must
not be too messy, smelly, easily detectable, or strong
tasting or interfere with sexual pleasure in other ways.
Research indicates that women will want the choice of
both contraceptive and non›contraceptive microbi›
cides. Drawing on spermicide technologies, research›
ers are investigating a range of delivery systems
including gels, films, sponges, and foaming tablets.
Status of microbicides tested in human
trials
The first product to be tested in efficacy trials was non›
oxinol 9. Although it was already widely used as a sper›
micide, safety studies were repeated in women in
Europe, Thailand, and South Africa as the compound
had a low selectivity index (activity against HIV
compared with cytotoxicity against epithelial cells). The
results of these studies justified proceeding to efficacy
trials, and two such trials were reported by the end of
1999.7 8 Their results, and preliminary results from a
study in commercial sex workers, suggest that nonoxi›
nol 9 actually increases HIV transmission, probably
because of local genital toxicity. The toxicity in these
studies may have been associated with frequency of
use, and analyses to address this are under way.
However, these findings underline the importance of
continuing to monitor safety in efficacy trials.
The table summarises the range of agents currently
being assessed in human trials. Most are still at the
early stages of safety studies. The next products likely
to reach efficacy trials belong to the class that blocks
HIV entry into host cells. These compounds have a
much higher selectivity index than nonoxinol 9 in
vitro, and toxicity experiments in animal models have
been satisfactory. Preliminary safety studies have been
completed in healthy female volunteers in the United
Kingdom, Belgium, the United States, and South
Africa for PRO 2000, a sulphonated polymer, and in
the United Kingdom and Belgium for the sulphated
polysaccharide dextrin sulphate. These two products
will enter expanded safety studies in 2001 in Uganda
(women attending a gynaecology clinic) and Côte
d’Ivoire (commercial sex workers) as part of the micro›
bicide programme funded by the European Commis›
sion. The Population Council (www.popcouncil.org) is
similarly developing carrageenan and is sponsoring a
large safety study in women attending a family
planning clinic in South Africa. Family Health
International plans to investigate Buffer Gel, a pH 4.5
vaginal buffering agent, and are setting up an efficacy
trial in Malawi and Zimbabwe in collaboration with the
National Institute of Health’s HIV Prevention Network
(www.fhi.org/en/aids/hptn/hptn.html).
Status of products in preclinical
development
In vitro studies have identified many molecules with
apparent potential as vaginal microbicides that have
not yet been tested extensively in humans. Figure 1
details compounds that act specifically against HIV or
block cell surface receptors. For compounds that act
directly against the virus—for example, before integra›
tion of the virus into genetic material—it will be vital to
check that drug resistance does not emerge, and for
those that block cell surface receptors it will be neces›
sary to ensure that they are not circumvented by the
virus interacting with other receptors. Various
microbicidal peptides with action against HIV have
been described, both synthetic and those based on
natural peptides such as defensins and magainins.
Other compounds with encouraging antimicrobial
Potential microbicides currently in human trials
Activity
Product groups and active agents Anti›STI Spermicidal Human trials
Broad spectrum activity
Non›ionic surfactants:
Nonoxinol 9* ++ + Efficacy
Chlorhexidine* ++ + Efficacy (vertical transmission)
Octoxinol 9* ++ + Safety
Anionic surfactants:
Docusate sodium* ++ NA Safety
Cationic surfactants:
Glyminox (C31G)* ++ + Safety
Benzalkonium chloride* ++ NA Safety
Geda plus* ++ + Safety
Acid buffers:
Buffer gel ++ +/− Safety
Plant extracts:
Praneem polyherbal ++ + Safety
Gossypol NA + Safety
Bacteria:
Lactobacilli − − Safety
Peptides:
IB367 (protegrin) + NA Safety
Inhibitors of viral entry
Sulphated polysaccharides:
Dextrin sulphate + − Safety
Carrageenan ++ NA Safety
Cellulose sulphate ++ − Safety
Sulphonated polymers:
PRO 2000 ++ − Safety
Inhibitors of viral replication
Reverse transcriptase inhibitors:
Tenofovir (PMPA) − − Safety (oral administration)
STI=sexually transmitted infection. NA=not assessed. *Known to be cytotoxic to HIV.
Disable
the virion
Block entry
into host cell
After entry,
block integration
of genetic
material
Nonoxinol 9
CAP
(high concentration)
Dextrin sulphate
PRO 2000
CAP
(low concentration)
NNRTI
Fig 1 Modes of action of new vaginal microbicides. (CAP=cellulose
acetate phthalate; NNRTI=non›nucleoside reverse transcriptase
inhibitor)
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profiles include cellulose acetate phthalate, a pharma›
ceutical additive already used in oral preparations, and
CTC›96, an organocobalt compound.
Challenges for evaluation
Like other new drugs, vaginal microbicides must be
evaluated in preclinical studies, in small scale trials of
safety and acceptability, and finally in large scale field
trials of efficacy against target infections (fig 2 ). Careful
consideration must be given to ethical issues and to
ensuring appropriate procedures for informed con›
sent. Since many of the trials are conducted in
developing countries, ethical approval for microbicide
studies is often sought from a developed country,
where approval mechanisms are better established, as
well as the host country.
Testing safety and acceptability
Although initial trials of safety and acceptability focus
on women, they must also include evaluation of male
partners. Acceptable, practical, and standardised
methods are needed for assessing toxicity to the vagi›
nal mucosa by the naked eye and colposcopy, such as
those proposed by the International Working Group
on Microbicides.9 Risks to participants in trials must be
minimised by protection from pregnancy and screen›
ing to exclude sexually transmitted infections and
HIV. Microbicides are likely to be most effective at
population level if they both protect uninfected
women against HIV infection and reduce the
infectiousness of women already infected. Trials there›
fore also need to check safety of microbicides in
infected women; they could also study effects on levels
of HIV RNA in vaginal swabs as a proxy for
infectiousness. Because epidemiological and cultural
conditions vary so greatly, studies of safety and accept›
ability are needed in all likely target populations.
Other factors that need to be assessed before an
efficacy trial are the distribution and retention of
microbicide in the vagina.
Efficacy trials
Initial trials of efficacy against HIV acquisition involve
women not infected with HIV. Effects on other sexually
transmitted infections should also be measured, both
as an important health issue in its own right and
because such infections enhance HIV transmission10
and microbicides might affect HIV spread through this
indirect mechanism.
A placebo control group is needed to reduce bias
and to distinguish the product’s effect from any
changes in behaviour that might result from the provi›
sion of such a product. Investigators must therefore
ensure that all participants understand they may
receive an inactive product and should not assume
they are protected. Condoms must be made available
to participants if they choose to use them. Previous
trials have shown increased condom use by partici›
pants, and trial size should allow for this. The ethical
justification for a placebo group is that before the trial
it is not known whether the product has any beneficial
or adverse effect. Although lack of benefit may seem
implausible on the basis of preclinical and early clinical
studies, the experience with nonoxinol 9 shows that
promising products may prove ineffective or even
harmful in efficacy trials.7 8
In general, study populations with a high incidence
of HIV infection are needed for efficacy trials in order
to reduce the number of participants required. All
trials will require baseline screening to identify women
not infected with HIV. Potential study groups might
include commercial sex workers,7 women attending
clinics for sexually transmitted infections, women
whose male partner is already infected, or women in
the general population where incidence is sufficiently
high (such as in South Africa11) who could be recruited
postnatally or through maternal and child health clin›
ics, family planning clinics, or voluntary HIV testing
sites. All studies face the challenge of achieving
adequate follow up rates.
Trials in women infected with HIV
Microbicides are initially being developed to protect
uninfected women from HIV, but infected women
would also use them if they reduced transmission of
HIV and other sexually transmitted infections to male
partners. The combined effect at population level of
moderate protection against both acquisition and
transmission of HIV could be substantial, as has been
predicted for HIV vaccines.12 Effects on infectiousness
could be assessed in an efficacy trial in couples where
the woman is infected with HIV and the man is not.
Innovative designs have been proposed for trials of
HIV vaccines, and these might be adapted for microbi›
cide trials.13
From efficacy to effectiveness
A distinction can be made between trials measuring
the efficacy of an intervention when delivered
optimally and those measuring its effectiveness when
used in practical conditions. Even in a carefully
conducted trial compliance with microbicide use may
be suboptimal, so data interpretation must take
account of trial records on product use and acceptabil›
ity and concurrent condom use.
Use of a microbicide might also be associated with
risk compensation.14 Women may perceive that they
are protected by the product and consequently
increase their exposure either through an increased
number of sexual partners or decreased condom use. It
would be important to seek evidence of any such effect
in efficacy trials.
Preclinical
 toxicity
In vitro assessment of activity and cytotoxicity
Elucidation of molecular mechanisms underlying activity
Parallel studies collecting behavioural,
health economic, and social marketing data
Acceptability and optimisation of formulation and delivery
Expanded safety in target population
Feasibility target population
Phase II run in to Phase III
Phase I Phase II
Fig 2 Stages of microbicide development
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Challenges for implementation
To be widely used, microbicides must be both
affordable and acceptable to women and men. Ease of
delivery and lack of detectability will probably be
crucial, and product delivery systems must be adapted
to local cultural and sexual preferences, such as the use
of dessicants for “dry sex.”15
Access to supplies is another issue. In some African
countries condoms are provided freely or at very low
cost, but many rural villages have no local outlet.
Special programmes may be needed, such as through
recruitment of villagers to become product marketers.
Where there is a good network of primary health units,
free supplies might be offered to women through such
units. Supplies might be linked to established family
planning programmes to offer a range of prevention
options. However, it would be important not to have
the unintended effect of decreasing condom use, as this
may ultimately remain more effective in preventing
HIV transmission.
Future directions
A combination of effective intervention strategies is
needed to reduce transmission of HIV. This is
important in all age groups, but particularly so in ado›
lescents. Such strategies may include delay in sexual
debut, reducing the number of casual sexual partners,
use of condoms, and prompt and effective treatment of
sexually transmitted infections, as well as use of micro›
bicides.
Speeding up microbicide development and deliv›
ery to countries where HIV is the greatest threat will
require a concerted multidisciplinary and international
effort. Public and industrial investment in product
development must be combined with an efficient and
rapid system of evaluation through clinical studies
involving basic scientists, epidemiologists, triallists, and
behavioural scientists.
There is a good prospect that at least one safe and
effective product will become available for widespread
use within the next five to 10 years. This would be an
important step forward in efforts to bring the HIV epi›
demic under control in Africa and other parts of the
developing world.
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Endpiece
Filled with wonder
With no medical or scientific training, Manuel Garcia’s only desire
was to see a “healthy glottis exposed in the very act of singing.”
How this Spanish singing professor made his discovery of
indirect laryngoscopy is legend:
“One September day in 1854, I was strolling in the garden of
the Palais Royal, preoccupied with the ever›recurring wish so
often repressed as unrealisable, when suddenly I saw the two
mirrors of the laryngoscope in their respective positions, as if
actually present before my eyes. I went straight to CharriŁre, the
surgical instrument maker, and asking if he happened to possess
a small mirror with a long handle, was informed that he had a
little dentist’s mirror, which had been one of the failures of the
London Exhibition of 1851. I bought it for six francs. Having
obtained also a hand mirror, I returned home at once, very
impatient to begin my experiements. I placed against the uvula
the little mirror (which I had heated in warm water and carefully
dried) and by flashing upon its surface with the hand mirror a ray
of sunlight, I saw at once, to my great joy, the glottis wide open
before me, and so fully exposed that I could perceive a portion of
the trachea. When my excitement had somewhat subsided, I
began to examine what was passing before my eyes. The manner
in which the glottis silently opened and shut, and moved in the
act of phonation, filled me with wonder.”
Manuel Patricio Rodriguez Garcia Transactions of the Section of
Laryngology, International Congress of Medicine, London, 1881
Submitted by Dr S Alam Hannan, basic surgical trainee, London
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